Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Stock Information for Organovo Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Organovo Holdings Inc.

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.